High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma

BACKGROUND: Clinical trials of anti-CCR4 antibody for solid cancers with or without other immune-modulating agents including immune checkpoint blockade therapy are currently underway. However, little is known about the roles of CCR4(+) lymphocytes and their prognostic impact in lung cancer. We hypot...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Thorac Dis
Autors principals: Karasaki, Takahiro, Qiang, Guangliang, Anraku, Masaki, Sun, Yanbin, Shinozaki-Ushiku, Aya, Sato, Eiichi, Kashiwabara, Kosuke, Nagayama, Kazuhiro, Nitadori, Jun-ichi, Sato, Masaaki, Murakawa, Tomohiro, Kakimi, Kazuhiro, Fukayama, Masashi, Nakajima, Jun
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2018
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6129889/
https://ncbi.nlm.nih.gov/pubmed/30233846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.07.45
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars